Shilpa announces the launch of NODUCATM for the first time in India to treat metabolic dysfunction associated fatty liver disease (MAFLD)
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare has launched NODUCATM in India, positioning it as the first product of its kind available domestically for treating Metabolic dysfunction Associated Fatty Liver Disease (MAFLD). MAFLD is a growing liver health concern linked to obesity and diabetes. The launch expands the company's product portfolio into the metabolic/liver disease therapy segment. No specific revenue projections or pricing details were disclosed in the announcement. The move aligns with Shilpa's strategy to grow its domestic branded formulations business.
This product launch adds a new revenue stream and could be a positive catalyst for the stock if NODUCATM gains market traction, though the near-term financial impact is likely modest given the early stage of commercialization.